WASHINGTON (AP) -- Federal regulators have scheduled a meeting to review the safety of Bayer AG’s blood-clotting drug Trasylol, which has been under government scrutiny for more than a year. The Food and Drug Administration will ask a group of outside experts on Sept. 12 to look at data suggesting Trasylol can cause kidney damage, heart failure and even death, according to a posting on the FDA’s Web site Wednesday.
